Akebia Therapeutics, Inc.
NASDAQ:AKBABiotechnology
+$0.01 today
- Market cap
- $113.54M
- Beta
- 0.25
- P/E (TTM)
- -13.3
- EPS (TTM)
- -$0.08
Volume 7.09M
Average 4.03M
AKBA EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Akebia Therapeutics, Inc.NASDAQ: AKBA
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA turns negative
Q1 FY2026 EBITDA was -$13.29M, compared with $14.2M a year earlier. Trailing-twelve-month EBITDA was -$5.76M. Over 3 fiscal years it compounded at +92.3% a year.
Context
- EBITDA amounted to 9.2% of revenue in FY2025, up 0.6 pp from a year earlier.
- EBITDA increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 4 analysts of -$31.27M (-243.9%) for the fiscal year ending Dec 2026, a slowdown from the +258.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$13.29M-118.4% QoQ
- Last fiscal yearDec 2025
- $21.73M+258.3% YoY
- LTMMar 2026
- -$5.76M-220.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -193.6% | -167.6% | +26.1 pp |
| 1 year | +258.3% | -243.9% | -502.3 pp |
| 3-year CAGR | +92.3% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 21.73M USD
- Year-over-year change
- +258.3%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 21.73M | +258.3% |
| FY2024 | 2024-12-31 | (13.72M) | -66.0% |
| FY2023 | 2023-12-31 | (8.27M) | -370.5% |
| FY2022 | 2022-12-31 | 3.06M | +101.6% |
| FY2021 | 2021-12-31 | (189.91M) | — |
EBITDA vs competitors
How AKBA compares with its peers on the latest reported figures
- AKBA's LTM Mar 2026 EBITDA of -$5.76M is the 3rd highest of the 10 companies compared; the peer median is -$74.72M.
- Its year-over-year change of -220.1% is the 8th highest of 9, against a peer median of +0.8%.
- EBITDA amounts to 2.5% of revenue for AKBA, versus a peer median of 121.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $140.47M | +332.9% | — | 114.9% | |
| LTM Mar 2026 | $131.28M | +170.9% | — | 43.8% | |
| LTM Mar 2026 | -$5.76M | -220.1% | +92.3% | 2.5% | |
| LTM Mar 2026 | -$42.27M | -2.3% | — | — | |
| LTM Mar 2026 | -$67.05M | -25.2% | — | — | |
| LTM Mar 2026 | -$74.72M | +35.0% | — | 129.0% | |
| LTM Dec 2025 | -$117.15M | — | — | 101.1% | |
| LTM Mar 2026 | -$163.43M | +3.9% | — | 185.2% | |
| LTM Mar 2026 | -$168.81M | -372.8% | — | 304.0% | |
| LTM Mar 2026 | -$184.67M | -43.8% | — | — | |
| Peer median (excluding AKBA) | -$74.72M | +0.8% | — | 121.9% | |
Competitors are the stored peer set for AKBA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 211.65M | 292.48M | 194.62M | 160.18M | 236.2M |
| Cost of Revenue | 81.49M | 22.5M | 74.15M | 63.18M | 39.46M |
| Gross Profit | 130.16M | 269.99M | 120.47M | 97M | 196.73M |
| Gross Margin | 61.5% | 92.3% | 61.9% | 60.6% | 83.3% |
| Research & Development | 147.85M | 165.99M | 63.08M | 37.65M | 62.36M |
| Selling, General & Admin | 174.14M | 138.6M | 100.23M | 106.55M | 107.48M |
| Operating Expenses | 394.66M | 350.77M | 166.73M | 147.48M | 173.24M |
| Depreciation & Amortization | 37.97M | 37.7M | 37.63M | 37.5M | 1.27M |
| EBITDA | (189.91M) | 3.06M | (8.27M) | (13.72M) | 21.73M |
| EBITDA Margin | -89.7% | 1.0% | -4.2% | -8.6% | 9.2% |
| Operating Income | (264.5M) | (80.78M) | (46.26M) | (50.47M) | 23.5M |
| Operating Margin | -125.0% | -27.6% | -23.8% | -31.5% | 9.9% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 19.94M | 15.69M | 6.03M | 18.19M | 24.18M |
| Other Income / Expenses | (17.52M) | (13.45M) | (5.67M) | (18.94M) | (27.22M) |
| Income Before Tax | (282.02M) | (94.23M) | (51.93M) | (69.41M) | (3.72M) |
| Pre-Tax Margin | -133.3% | -32.2% | -26.7% | -43.3% | -1.6% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 1.62M |
| Net Income | (282.02M) | (94.23M) | (51.93M) | (69.41M) | (5.35M) |
| Net Margin | -133.3% | -32.2% | -26.7% | -43.3% | -2.3% |
| EPS (Basic) | (1.48) | (0.58) | (0.28) | (0.33) | (0.02) |
| EPS (Diluted) | (1.48) | (0.58) | (0.28) | (0.33) | (0.02) |
| Weighted Avg Shares | 165.95M | 182.78M | 187.47M | 210.95M | 257.16M |
| Weighted Avg Shares (Diluted) | 165.95M | 182.78M | 187.47M | 210.95M | 257.16M |
Akebia Therapeutics, Inc.
NASDAQ:AKBA
Intrinsic Alpha fair value
Locked
Current Price
$0.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.